Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors
Clinical trial NCT04226066 · UNKNOWN
Trial details
- NCT number
- NCT04226066
- Sponsor
- Tasly Tianjin Biopharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-20
- Primary completion
- 2021-05-31
- Enrollment
- 69
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.